|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 6 (March 15), 2000:
pp. 1925-1930
Deletion of 13q14 remains an independent adverse prognostic
variable in multiple myeloma despite its frequent detection by
interphase fluorescence in situ hybridization
Niklas Zojer,
Robert Königsberg,
Jutta Ackermann,
Elke Fritz,
Susanne Dallinger,
Elisabeth Krömer,
Hannes Kaufmann,
Lucia Riedl,
Heinz Gisslinger,
Susanne Schreiber,
Renate Heinz,
Heinz Ludwig,
Heinz Huber, and
Johannes Drach
From the Department of Internal Medicine I, Division of Clinical
Oncology, Division of Hematology and Hemostesiology, University of
Vienna; Department of Internal Medicine I with Medical Oncology,
Wilhelminenspital; Ludwig Boltzmann Institute for Leukemia
Research and Hematology; and the Third Department of Internal
Medicine, Hanuschspital, Vienna, Austria.
Interphase fluorescence in situ hybridization (FISH) studies of
chromosomal region 13q14 were performed to investigate the incidence
and clinical importance of deletions in multiple myeloma (MM).
Monoallelic deletions of the retinoblastoma-1 (rb-1) gene and the
D13S319 locus were observed in 48 of 104 patients (46.2%) and in 28 of
72 (38.9%) patients, respectively, with newly diagnosed MM. FISH
studies found that 13q14 was deleted in all 17 patients with karyotypic
evidence of monosomy 13 or deletion of 13q but also in 9 of 19 patients
with apparently normal karyotypes. Patients with a 13q14 deletion were
more likely to have stage III disease (P = .022),
higher serum levels of  2-microglobulin (P = .059), and a higher percentage of bone marrow plasma cells
(P = .085) than patients with a normal 13q14 status on FISH
analysis. In patients with a deletion of 13q14, myeloma cell
proliferation (Ki-67) was markedly increased (22.0% ± 6.9% compared
with 15.6% ± 8.2% in patients without the deletion;
P = .0008). Evaluation of bromodeoxyuridine incorporation
in 5 patients revealed that both rb-1-deleted and rb-1-normal MM
subpopulations were proliferative. The presence of a 13q14 deletion on
FISH analysis was associated with a significantly lower rate of
response to conventional-dose chemotherapy (40.8% compared with
78.6%; P = .009) and a shorter overall survival (24.2 months compared with > 60 months; P < .005) than in
patients without the deletion. Multivariate analysis of prognostic
factors confirmed the independent predictive value of 13q14 deletions
for shortened survival. In conclusion, deletions of 13q14 are
frequently detected by interphase FISH in patients with newly diagnosed
MM, correlate with increased proliferative activity, and represent an
independent adverse prognostic feature in MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M.-V. Mateos, J. M. Hernandez, M. T. Hernandez, N. C. Gutierrez, L. Palomera, M. Fuertes, P. Garcia-Sanchez, J. J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
Haematologica,
April 1, 2008;
93(4):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Heller, W. M. Schmidt, B. Ziegler, S. Holzer, L. Mullauer, M. Bilban, C. C. Zielinski, J. Drach, and S. Zochbauer-Muller
Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells
Cancer Res.,
January 1, 2008;
68(1):
44 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brousseau, X. Leleu, J. Gerard, T. Gastinne, A. Godon, F. Genevieve, M. Dib, J.-L. Lai, T. Facon, M. Zandecki, et al.
Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients
Clin. Cancer Res.,
October 15, 2007;
13(20):
6026 - 6031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
Blood,
June 1, 2007;
109(11):
4995 - 5001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Blood,
April 15, 2007;
109(8):
3489 - 3495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Agnelli, S. Bicciato, S. Fabris, L. Baldini, F. Morabito, D. Intini, D. Verdelli, A. Callegaro, F. Bertoni, G. Lambertenghi-Deliliers, et al.
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
Haematologica,
January 1, 2007;
92(1):
56 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood,
October 1, 2006;
108(7):
2165 - 2172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Blood,
September 1, 2006;
108(5):
1733 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Chen, B. Issa, S. Huang, E. Aston, J. Xu, M. Yu, A. R. Brothman, and M. Glenn
A Practical Approach to the Detection of Prognostically Significant Genomic Aberrations in Multiple Myeloma
J. Mol. Diagn.,
November 1, 2005;
7(5):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart and R. Fonseca
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
J. Clin. Oncol.,
September 10, 2005;
23(26):
6339 - 6344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Strasser-Weippl, M. Steurer, M. Kees, F. Augustin, A. Tzankov, S. Dirnhofer, M. Fiegl, H. Gisslinger, N. Zojer, and H. Ludwig
Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia
Blood,
May 15, 2005;
105(10):
4146 - 4146.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Gutierrez, J. L. Garcia, J. M. Hernandez, E. Lumbreras, M. Castellanos, A. Rasillo, G. Mateo, J. M. Hernandez, S. Perez, A. Orfao, et al.
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Blood,
November 1, 2004;
104(9):
2661 - 2666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, et al.
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
Blood,
June 1, 2004;
103(11):
4056 - 4061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kaufmann, J. Ackermann, H. Greinix, T. Nosslinger, H. Gisslinger, A. Keck, H. Ludwig, N. Worel, P. Kalhs, C. Zielinski, et al.
Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
Ann. Onc.,
November 1, 2003;
14(11):
1667 - 1672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, E. Blood, M. Rue, D. Harrington, M. M. Oken, R. A. Kyle, G. W. Dewald, B. Van Ness, S. A. Van Wier, K. J. Henderson, et al.
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Blood,
June 1, 2003;
101(11):
4569 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy, J. Jacobson, J. Sawyer, J. McCoy, A. Fassas, F. Zhan, K. Bumm, J. Epstein, E. Anaissie, S. Jagannath, et al.
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
Blood,
May 15, 2003;
101(10):
3849 - 3856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Segeren, P. Sonneveld, B. van der Holt, E. Vellenga, A. J. Croockewit, G. E. G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H. J. van Oers, P. W. Wijermans, et al.
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
Blood,
March 15, 2003;
101(6):
2144 - 2151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood,
February 15, 2003;
101(4):
1220 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Filipits, G. Pohl, T. Stranzl, H. Kaufmann, J. Ackermann, H. Gisslinger, H. Greinix, A. Chott, and J. Drach
Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma
Clin. Cancer Res.,
February 1, 2003;
9(2):
820 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Laterveer, L. F. Verdonck, T. Peeters, E. Borst, A. C. Bloem, and H. M. Lokhorst
Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma
Blood,
February 1, 2003;
101(3):
1201 - 1201.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreau, T. Facon, X. Leleu, N. Morineau, P. Huyghe, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
Blood,
August 13, 2002;
100(5):
1579 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, T. Facon, B. Grosbois, F. Magrangeas, M.-J. Rapp, J.-L. Harousseau, S. Minvielle, and R. Bataille
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
Blood,
March 15, 2002;
99(6):
2185 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R. Sanderson, Y. Yang, C. Wilson, M. Zangari, et al.
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
Blood,
March 1, 2002;
99(5):
1745 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, D. Harrington, M. M. Oken, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, E. A. Blood, S. V. Rajkumar, N. E. Kay, et al.
Biological and Prognostic Significance of Interphase Fluorescence in Situ Hybridization Detection of Chromosome 13 Abnormalities ({Delta}13) in Multiple Myeloma: An Eastern Cooperative Oncology Group Study
Cancer Res.,
February 1, 2002;
62(3):
715 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart
Hypodiploidy is a major prognostic factor in multiple myeloma
Blood,
October 1, 2001;
98(7):
2229 - 2238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bullrich, H. Fujii, G. Calin, H. Mabuchi, M. Negrini, Y. Pekarsky, L. Rassenti, H. Alder, J. C. Reed, M. J. Keating, et al.
Characterization of the 13q14 Tumor Suppressor Locus in CLL: Identification of ALT1, an Alternative Splice Variant of the LEU2 Gene
Cancer Res.,
September 1, 2001;
61(18):
6640 - 6648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Facon, H. Avet-Loiseau, G. Guillerm, P. Moreau, F. Genevieve, M. Zandecki, J.-L. Lai, X. Leleu, J.-P. Jouet, F. Bauters, et al.
Chromosome 13 abnormalities identified by FISH analysis and serum {beta}2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
Blood,
March 15, 2001;
97(6):
1566 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, A. Daviet, C. Brigaudeau, E. Callet-Bauchu, C. Terre, M. Lafage-Pochitaloff, F. Desangles, S. Ramond, P. Talmant, and R. Bataille
Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique
Blood,
February 1, 2001;
97(3):
822 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology,
January 1, 2001;
2001(1):
157 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr, E. Tian, J. Sawyer, K. Bumm, R. Landes, A. Badros, C. Morris, G. Tricot, J. Epstein, and B. Barlogie
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
Blood,
August 15, 2000;
96(4):
1505 - 1511.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
